Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-inhuman study.

Antoni Vilaseca, Felix Guerrero, Daniel Zainfeld,Neal D. Shore, Oscar Rodriguez Faba,Richard P. Meijer,Alfred Alfred Witjes,Autumn Jackson McRee,Anna Kalota,Nicole L. Stone,Josh David Lauring, Wei Zhu,Neil Beeharry, Lang A. O'Dondi,Gautam Jayram

JOURNAL OF CLINICAL ONCOLOGY(2023)

引用 0|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要